跳至主要内容
临床试验/EUCTR2018-003083-30-BE
EUCTR2018-003083-30-BE进行中(未招募)1 期

The effect of hydroxychloroquine sulphate on hedonic food intake, appetite-related sensations and gastrointestinal hormone release in healthy female subjects - PLAQHV

Z Leuven0 个研究点目标入组 10 人开始时间: 2019年1月2日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Female

入选标准

  • Subject is female between 18 and 65 years of age.
  • Subject has a BMI between 18 and 25 kg/m² and has a stable body weight for at least 3 consecutive months at the start of the study and keeps a stable weight during the study visits.
  • Subject is allowed to take 2 Plaquenil capsuls for one visit with a maximal dose of 6.5 mg hydroxychloroquine sulphate per kg bodyweight.
  • Women of child-bearing potential agree to apply during the entire duration of the trial a highly effective method of birth control, which is defined as those which result in a low failure rate (i.e., less than 1% per year) when used constantly and correctly such as implants, injectables, combined oral contraceptive method, or some intrauterine devices (IUDs), sexual abstinence, or vasectomized partner. Women of non-childbearing potential may be included if surgically sterile (tubal ligation or hysterectomy) or postmenopausal with at least 2 year without spontaneous menses.
  • Subject understands the study procedures and agrees to participate in the study by giving written informed consent.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 10
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Subject is under age of legal consent, male, pregnant or breastfeeding.
  • Subject with a BMI = 18 kg/m² or BMI = 25 kg/m².
  • Subject weight less than 62 kg.
  • Subject is currently following a weight loss diet.
  • Subject has current symptoms or a history of gastrointestinal or other significant somatic or psychiatric diseases or drug allergies.
  • Subject has diabetes.
  • Subject has a significant heart, lung, liver or kidney disease.
  • Subject has any history of a neurological disorder.
  • Subject has a history of abdominal surgery. Those having undergone a simple appendectomy more than 1 year prior to the screening visit may participate.
  • Subject has retinopathy.
  • Subject suffers from psoriasis.
  • Subject has porphyria.
  • Subject shows abnormal eating behavior or has an eating disorder.
  • History or current use of drugs that can affect glycaemia, gastrointestinal function, motility or sensitivity or gastric acidity.
  • History or current use of centrally acting medication, including antidepressants, antipsychotics and/or benzodiazepines (in the last year before screening visit).
  • Subject consumes excessive amounts of alcohol, defined as >14 units per week for women and >21 units per week for men.
  • Subject is currently (defined as within approximately 1 year of the screening visit) a regular or irregular user (including recreational use”) of any illicit drugs (including marijuana) or has a history of drug (including alcohol) abuse. Further, patient is unwilling to refrain from the use of drugs during this study.
  • High caffeine intake (> 4 cups of coffee daily or equivalent).
  • Inability or unwillingness to perform all of the study procedures, or the subject is considered unsuitable in any way by the principal investigator.
  • Recent participation (<30 days) or simultaneous participation in another clinical study.
  • Subjects with lactose intolerance.
  • Subjects with quinine allergy.

研究者

发起方
Z Leuven

相似试验